Tag: The Netherlands
Company News: ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Hendrik-Jan Laseur to its Supervisory Board.
Hendrik-Jan Laseur has an outstanding track record in advising foundations, non-governmental organizations and financial institutions. Among others, he currently serves as a Board member of the Center for Public Integrity (Washington, DC, USA), as a member of the Advisory Board of SustainAbility (London, UK) and as a Board member of the Adessium Foundation (Rotterdam, The Netherlands).
Hendrik-Jan Laseur is the founder of Laseur – Lead the Change, an Amsterdam-based strategy advisory firm focused on supporting leaders in achieving lasting social impact of investments and business propositions. Clients include non-governmental organizations, civil society organizations, philanthropic foundations, financial institutions, and the United Nations.
Prior to founding Laseur in 2010, he was Principal Advisor of the Executive Director at UNICEF, where he worked on resource allocation, strategy, finance and funding issues.
From 1992 to 2007, Hendrik-Jan Laseur worked at ABN Amro Bank in a variety of leadership and advisory positions in Tokyo, Frankfurt, London, Amsterdam and Zurich, including roles as personal secretary to the Chairman of the bank, and as a member of the Executive Committee of ABN AMRO Switzerland.
Hendrik-Jan Laseur studied economics in Groningen and Rotterdam and holds an MBA from INSEAD.
Company News: New Favorable Clinical Evaluation Data for Unyvero™ P50 Pneumonia Application
– Dutch study demonstrates excellent sensitivity of Unyvero™ cartridges –
Curetis AG, a developer of next-level molecular diagnostic solutions, today announced positive clinical data from an independent study conducted by researchers from the Department of Medical Microbiology of Maastricht University Medical Center (MUMC), Maastricht, the Netherlands. The data demonstrate the high clinical sensitivity of the Unyvero™ P50 Pneumonia application in detecting pathogens, including samples with low pathogen concentrations.
The researchers compared the performance of the Unyvero™ P50 cartridge with conventional microbiology culture in broncho-alveolar lavage fluid (BALF) samples for the diagnosis of ventilator-associated pneumonia (VAP), a common complication in intensive care patients. The most frequent causes are Pseudomonas aeruginosa, Staphylococcus aureus and Enterobacteriaceae.
Using the quantitative culture standard, Unyvero™ P50 Pneumonia correctly detected 8 different important pathogens in all VAP samples (n=44) at 100% sensitivity. The overall sensitivity of the Unyvero™ P50 panel was 88.6% at clinically relevant pathogen concentration. Unyvero™ P50 was also able to detect 8 different clinically relevant pathogens in 12 patient samples where conventional microbiology culture failed. This data confirms previous results where Unyvero™ had consistently detected pathogens missed by conventional culture.
The data were presented at the Scientific Spring Meeting of the Koninklijke Nederlandse Vereniging voor Microbiologie (Royal Dutch Society for Microbiology) KNVM and Nederlandse Vereniging voor Medische Milieukunde (Dutch Association for Environmental Medicine) NVMM 2014 in Arnhem, The Netherlands.